NASDAQ:SKYE | Free Cash Flow | Skye Bioscience, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2012-10-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$8.56M$0.00-$8.56M
2025-12-31-$9.77M$0.00-$9.77M
2025-03-31-$9.19M$6,312.00-$9.19M
2024-12-31-$8.17M$50,024.00-$8.22M
2024-03-31-$4.71M$3,181.00-$4.71M
2023-12-31-$3.84M$7,017.00-$3.85M
2023-03-31-$4.06M$1,860.00-$4.06M
2022-12-31-$4.87M$12,504.00-$4.88M
2022-03-31-$2.91M$1,999.00-$2.92M
2021-12-31-$1.97M$54,038.00-$2.02M
2021-03-31-$1.35M$10,696.00-$1.36M
2020-12-31-$1.79M$7,230.00-$1.79M
2020-03-31-$1.27M$0.00-$1.27M
2019-12-31-$1.5M
2019-03-31-$1.43M
2018-12-31-$1.01M$0.00-$1.01M
2018-03-31-$1.05M$1,059.00-$1.05M
2017-12-31-$2.14M
2017-03-31-$816,405.00
2016-12-31-$662,778.00$1.00-$662,779.00
2016-03-31-$1.15M$11,116.00-$1.16M
2015-12-31-$1.11M$0.00-$1.11M
2015-03-31-$751,694.00
2014-12-31-$802,640.00$10,873.00-$813,513.00
2014-01-31-$4,145.00
2013-10-31-$8,756.00$0.00-$8,756.00
2013-01-31-$12,489.00$47,471.00-$59,960.00-37475.00%
2012-10-31$1,525.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$43.06M$6,312.00-$43.07M
2024-12-31-$25.24M$1.6M-$26.84M
2023-12-31-$13.95M$12,550.00-$13.96M
2022-12-31-$12.74M$28,060.00-$12.77M
2021-12-31-$6.47M$90,866.00-$6.57M
2020-12-31-$6.05M$7,230.00-$6.06M
2019-12-31-$6.03M
2018-12-31-$3.94M$4,385.00-$3.95M
2017-12-31-$3.33M$19,654.00-$3.35M
2016-12-31-$3.55M$11,117.00-$3.56M
2015-12-31-$3.73M$1,982.00-$3.73M
2014-12-31-$1.76M$23,262.00-$1.78M
2013-10-31-$14,495.00$49,116.00-$63,611.00
2012-10-31$1,928.00

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.